Castle Biosciences, Inc. has secured $64.0 million in investment capital from investors. The Friendswood, TX-based company is a leading diagnostics firm focused on improving health through innovative tests that guide patient care. Castle Biosciences aims to transform disease management by developing proprietary tests that address unmet clinical needs across the patient care continuum.
The company currently markets five proprietary tests designed to answer clinical questions and address treatment plan challenges for physicians. These tests primarily serve the fields of dermatologic cancers, Barrett’s esophagus, and uveal melanoma. For instance, DecisionDx®-Melanoma is a gene expression profile (GEP) test that predicts the risk of metastasis or recurrence in patients with invasive cutaneous melanoma. Similarly, DecisionDx®-SCC predicts metastasis risk in cutaneous squamous cell carcinoma, and TissueCypher® Barrett’s Esophagus predicts the future development of esophageal cancer.
This capital infusion underscores investor confidence in Castle Biosciences' diagnostic platform and its market strategy. The $64.0 million in funding will be strategically deployed to support the company's ongoing growth initiatives. Castle Biosciences plans to allocate the funds towards advancing its research and development pipeline, expanding the commercial reach of its existing diagnostic tests, and enhancing its operational capabilities to meet increasing demand.
The investment is expected to strengthen Castle Biosciences' position in the precision medicine diagnostics market. With this additional capital, the company is poised to accelerate its mission of delivering innovative solutions that provide actionable insights for clinicians and improve patient outcomes, driving continued expansion and market penetration in its target disease areas.
.png&w=3840&q=75)
